Breast Cancer in the United States: A Cross-Sectional Overview
Table 2
Clinical characteristics of breast cancer patients diagnosed between 2004 and 2016.
Variable
# (%)
Charlson/Deyo comorbidity score
0
2,259,335 (85%)
1
325,670 (12%)
2
64,289 (2.4%)
≥3
22,255 (0.8%)
Clinical stage at diagnosis
0
534,244 (21%)
I
1,070,218 (42%)
II
647,845 (25%)
III
220,878 (8.6%)
IV
102,954 (4.0%)
Unknown
95,410
Secondary sites in patients diagnosed at stage IV
Bone
6,934 (68%)
Brain
793 (7.9%)
Liver
2,476 (25%)
Lung
3,072 (31%)
Molecular subtype
ER+ or PR+, HER2-
583,113 (58%)
ER+ or PR+, HER2+
258,750 (26%)
ER- and PR-, HER2-
104,175 (10%)
ER- and PR-, HER2+
64,947 (6.4%)
Unknown
1,660,564
Histological subtype
Ductal carcinoma
1,957,275 (73%)
Lobular carcinoma
402,325 (15%)
Adenocarcinoma of mixed types
1,669 (<0.1%)
Rare breast carcinomas
43,787 (1.6%)
Inflammatory invasive carcinoma
8,803 (0.3%)
Other carcinomas
186,368 (7.0%)
Intraductal papillary
19,330 (0.7%)
Papillary neoplasms
9,536 (0.4%)
Epithelial-myoepithelial
23,751 (0.9%)
Fibroepithelial tumors
3,498 (0.1%)
Metaplastic tumors
11,629 (0.4%)
Mesenchymal tumors
1,758 (<0.1%)
Tumors of the nipple
1,736 (<0.1%)
Carcinoid tumors
64 (<0.1%)
Malignant lymphoma
20 (<0.1%)
Grade
Well/moderately differentiated
1,535,058 (65%)
Poorly differentiated
792,145 (34%)
Undifferentiated
20,949 (0.9%)
Unknown
323,397
Any hormonal therapy
1,475,279 (87%)
Unknown
978,708
Any chemotherapy
907,505 (35%)
Unknown
89,559
Any immunotherapy
94,220 (3.6%)
Unknown
34,964
Any radiation therapy
1,389,019 (53%)
Unknown
29,641
Type of surgery
None
194,693 (7.3%)
Lumpectomy
1,459,286 (55%)
Mastectomy
1,007,588 (38%)
Unknown
9,982
Surgical margins
No surgery
194,693 (7.4%)
No residual disease
2,315,928 (88%)
Residual disease
109,716 (4.2%)
Unknown
51,212
The Charlson/Deyo index is a weighted score assessing overall comorbidity in patients by cross-referencing these cases to a list of international disease classification (ICD) codes known to be important prognosticators of morbidity and mortality [4]. The majority of stage IV patients did not have metastatic site documented, thus these percentages are reflective of the total number of cases for which data were available on this variable ( bone; brain; liver; lung).
